Cargando…

Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives

BACKGROUND: High-throughput RNA interference (RNAi) screens have been used to find genes that, when silenced, result in sensitivity to certain chemotherapy drugs. Researchers therefore can further identify drug-sensitive targets and novel drug combinations that sensitize cancer cells to chemotherape...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Fei, Bauer, Joshua A, Pietenpol, Jennifer A, Shyr, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535706/
https://www.ncbi.nlm.nih.gov/pubmed/23281588
http://dx.doi.org/10.1186/1471-2164-13-S8-S3
_version_ 1782254701434109952
author Ye, Fei
Bauer, Joshua A
Pietenpol, Jennifer A
Shyr, Yu
author_facet Ye, Fei
Bauer, Joshua A
Pietenpol, Jennifer A
Shyr, Yu
author_sort Ye, Fei
collection PubMed
description BACKGROUND: High-throughput RNA interference (RNAi) screens have been used to find genes that, when silenced, result in sensitivity to certain chemotherapy drugs. Researchers therefore can further identify drug-sensitive targets and novel drug combinations that sensitize cancer cells to chemotherapeutic drugs. Considerable uncertainty exists about the efficiency and accuracy of statistical approaches used for RNAi hit selection in drug sensitivity studies. Researchers require statistical methods suitable for analyzing high-throughput RNAi screening data that will reduce false-positive and false-negative rates. RESULTS: In this study, we carried out a simulation study to evaluate four types of statistical approaches (fold-change/ratio, parametric tests/statistics, sensitivity index, and linear models) with different scenarios of RNAi screenings for drug sensitivity studies. With the simulated datasets, the linear model resulted in significantly lower false-negative and false-positive rates. Based on the results of the simulation study, we then make recommendations of statistical analysis methods for high-throughput RNAi screening data in different scenarios. We assessed promising methods using real data from a loss-of-function RNAi screen to identify hits that modulate paclitaxel sensitivity in breast cancer cells. High-confidence hits with specific inhibitors were further analyzed for their ability to inhibit breast cancer cell growth. Our analysis identified a number of gene targets with inhibitors known to enhance paclitaxel sensitivity, suggesting other genes identified may merit further investigation. CONCLUSIONS: RNAi screening can identify druggable targets and novel drug combinations that can sensitize cancer cells to chemotherapeutic drugs. However, applying an inappropriate statistical method or model to the RNAi screening data will result in decreased power to detect the true hits and increase false positive and false negative rates, leading researchers to draw incorrect conclusions. In this paper, we make recommendations to enable more objective selection of statistical analysis methods for high-throughput RNAi screening data.
format Online
Article
Text
id pubmed-3535706
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35357062013-01-04 Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives Ye, Fei Bauer, Joshua A Pietenpol, Jennifer A Shyr, Yu BMC Genomics Research BACKGROUND: High-throughput RNA interference (RNAi) screens have been used to find genes that, when silenced, result in sensitivity to certain chemotherapy drugs. Researchers therefore can further identify drug-sensitive targets and novel drug combinations that sensitize cancer cells to chemotherapeutic drugs. Considerable uncertainty exists about the efficiency and accuracy of statistical approaches used for RNAi hit selection in drug sensitivity studies. Researchers require statistical methods suitable for analyzing high-throughput RNAi screening data that will reduce false-positive and false-negative rates. RESULTS: In this study, we carried out a simulation study to evaluate four types of statistical approaches (fold-change/ratio, parametric tests/statistics, sensitivity index, and linear models) with different scenarios of RNAi screenings for drug sensitivity studies. With the simulated datasets, the linear model resulted in significantly lower false-negative and false-positive rates. Based on the results of the simulation study, we then make recommendations of statistical analysis methods for high-throughput RNAi screening data in different scenarios. We assessed promising methods using real data from a loss-of-function RNAi screen to identify hits that modulate paclitaxel sensitivity in breast cancer cells. High-confidence hits with specific inhibitors were further analyzed for their ability to inhibit breast cancer cell growth. Our analysis identified a number of gene targets with inhibitors known to enhance paclitaxel sensitivity, suggesting other genes identified may merit further investigation. CONCLUSIONS: RNAi screening can identify druggable targets and novel drug combinations that can sensitize cancer cells to chemotherapeutic drugs. However, applying an inappropriate statistical method or model to the RNAi screening data will result in decreased power to detect the true hits and increase false positive and false negative rates, leading researchers to draw incorrect conclusions. In this paper, we make recommendations to enable more objective selection of statistical analysis methods for high-throughput RNAi screening data. BioMed Central 2012-12-17 /pmc/articles/PMC3535706/ /pubmed/23281588 http://dx.doi.org/10.1186/1471-2164-13-S8-S3 Text en Copyright ©2012 Ye et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ye, Fei
Bauer, Joshua A
Pietenpol, Jennifer A
Shyr, Yu
Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives
title Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives
title_full Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives
title_fullStr Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives
title_full_unstemmed Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives
title_short Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives
title_sort analysis of high-throughput rnai screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535706/
https://www.ncbi.nlm.nih.gov/pubmed/23281588
http://dx.doi.org/10.1186/1471-2164-13-S8-S3
work_keys_str_mv AT yefei analysisofhighthroughputrnaiscreeningdatainidentifyinggenesmediatingsensitivitytochemotherapeuticdrugsstatisticalapproachesandperspectives
AT bauerjoshuaa analysisofhighthroughputrnaiscreeningdatainidentifyinggenesmediatingsensitivitytochemotherapeuticdrugsstatisticalapproachesandperspectives
AT pietenpoljennifera analysisofhighthroughputrnaiscreeningdatainidentifyinggenesmediatingsensitivitytochemotherapeuticdrugsstatisticalapproachesandperspectives
AT shyryu analysisofhighthroughputrnaiscreeningdatainidentifyinggenesmediatingsensitivitytochemotherapeuticdrugsstatisticalapproachesandperspectives